Allianz Asset Management
ZNTL icon

Allianz Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Allianz Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,800
Closed -$377K – 2256
2023
Q3 		$377K Hold
18,800
– – ﹤0.01% 2014
2023
Q2 		$530K Buy
+18,800
New +$451K ﹤0.01% 1723
2022
Q2 		– Sell
-32,845
Closed -$1.52M – 2446
2022
Q1 		$1.52M Hold
32,845
– – ﹤0.01% 1702
2021
Q4 		$2.75M Sell
32,845
-7,860
-19% -$608K ﹤0.01% 1484
2021
Q3 		$2.71M Buy
40,705
+22,200
+120% +$1.28M ﹤0.01% 1536
2021
Q2 		$985K Hold
18,505
– – ﹤0.01% 1746
2021
Q1 		$803K Sell
18,505
-8,450
-31% -$364K ﹤0.01% 1726
2020
Q4 		$1.4M Hold
26,955
– – ﹤0.01% 1400
2020
Q3 		$881K Buy
+26,955
New +$944K ﹤0.01% 1462

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Allianz Asset Management's ZNTL Position: Q4 2023 in Review

Allianz Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 18,800 shares — an estimated $377K sold.

Allianz Asset Management first reported a position in ZNTL in Q3 2020 and held it in 9 quarters. The position peaked at $2.75M in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • Allianz Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Allianz Asset Management sold 18,800 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $377K.
  • Allianz Asset Management first reported a position in Zentalis Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Allianz Asset Management's Zentalis Pharmaceuticals position peaked at $2.75M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Allianz Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.